Fig. 4

The result of wound healing assay of primary cells derived from feline injection site sarcoma (FISS) treated with 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12) at different concentrations. The primary cells of FISS-10 were treated with different concentrations of LLL12. The width of the wounds was measured and photographed before the LLL12 treatment (T0) and at 24 h of treatment (T1). DMSO was used as the vehicle control